BioCryst Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on BioCryst Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date BioCryst Pharmaceuticals Inc Strategy Report
- Understand BioCryst Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
BioCryst Pharmaceuticals Inc (BioCryst) is a biotechnology company that designs, optimizes and develops small molecule drugs that block critical enzymes in the pathogenesis of diseases. The company focuses on the treatment of rare diseases and develops drugs for infectious diseases and hereditary angioedema. The company’s other pipeline products include, BCX10013 and BCX9250. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through a process known as structure-guided drug design. BioCryst’s products include peramivir injections, which consist of Rapivab, Alpivab, Rapiacta, Orladeyo and Peramiflu for the treatment of Influenza. BioCryst is headquartered in Durham, North Carolina, the US.
Headquarters
United States of America
Address
4505 Emperor Blvd Ste 200, Durham, North Carolina, 27703
Website
www.biocryst.com
Telephone
1 919 8591302
No of Employees
536
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BCRX (NASD)
Revenue (2022)
$331.4M
22.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
8.3%
(2022 vs 2021)
Market Cap*
$983.3M
Net Profit Margin (2022)
XYZ
25.1%
(2022 vs 2021)
* As of and is in US$
BioCryst Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Approved: | - |
| Rapivab (Peramivir injection): Acute uncomplicated Influenza | Peramiflu |
| Alpivab (Peramivir injection): Acute uncomplicated Influenza | Rapivab |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | New Products/Services | In February, the company introduced ORLADEYO (berotralstat) for the prevention of recurrent attacks of hereditary angioedema in patients 12 years and older. |
| 2023 | Contracts/Agreements | In November, the company entered into a partnership with Clearside Biomedical to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjector. |
| 2023 | Regulatory Approval | In November, the company received marketing authorization from the Spanish Ministry for Health for oral, once-daily ORLADEYO (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older. |
Competitor Comparison
| Key Parameters | BioCryst Pharmaceuticals Inc | F. Hoffmann-La Roche Ltd | GSK plc | Gilead Sciences Inc | Daiichi Sankyo Co Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | United Kingdom | United States of America | Japan |
| City | Durham | Basel | Brentford | Foster City | Chuo-Ku |
| State/Province | North Carolina | - | England | California | Tokyo |
| No. of Employees | 536 | 103,605 | 70,212 | 18,000 | 17,435 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Nancy Hutson | Chairman | Executive Board | 2023 | - |
| Jon P. Stonehouse | Chief Executive Officer; President; Director | Executive Board | 2007 | - |
| Anthony Doyle | Chief Financial Officer | Senior Management | 2020 | - |
| Philip George | Chief Strategy Officer | Senior Management | 2022 | - |
| Alane P. Barnes | Chief Legal Officer | Senior Management | 2018 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward